bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure
On June 5, 2017, bluebird bio, Inc. (bluebird) will be conducting
meetings with investors attending the American Society of
Clinical Oncology Annual Meeting.As part of these meetings,
bluebird will deliver the slide presentation furnished to this
report as Exhibit 99.1 and which is incorporated by reference
herein.
See Item 8.01 below, which is incorporated by reference herein.
The information in Item 7.01 of this Report on Form 8-K and
Exhibit 99.1 attached hereto is intended to be furnished and
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934 (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly
set forth by specific reference in such filing.
Item 8.01 Other Events
On June 5, 2017, bluebird issued a press release announcing
updated clinical data from its anti-BCMA CAR T cell therapy,
being presented at the American Society of Clinical Oncology
Annual Meeting on June 5, 2017.The full text of bluebirds press
release regarding the announcement is filed as Exhibit 99.2 to
this Current Report on Form 8-K and is incorporated herein by
reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 99.2 |
Investor presentation provided by bluebird bio, Inc. on
Press release issued by bluebird bio, Inc. on June 5, |
About bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
